Antibiotic use and outcomes among children hospitalized with suspected pneumonia

J Hosp Med. 2022 Dec;17(12):975-983. doi: 10.1002/jhm.13002. Epub 2022 Nov 15.

Abstract

Background: Although viral etiologies predominate, antibiotics are frequently prescribed for community-acquired pneumonia (CAP).

Objective: We evaluated the association between antibiotic use and outcomes among children hospitalized with suspected CAP.

Designs, settings and participants: We performed a secondary analysis of a prospective cohort of children hospitalized with suspected CAP.

Intervention: The exposure was the receipt of antibiotics in the emergency department (ED).

Main outcome and measures: Clinical outcomes included length of stay (LOS), care escalation, postdischarge treatment failure, 30-day ED revisit, and quality-of-life (QoL) measures from a follow-up survey 7-15 days post discharge. To minimize confounding by indication (e.g., radiographic CAP), we performed inverse probability treatment weighting with propensity analyses.

Results: Among 523 children, 66% were <5 years, 88% were febrile, 55% had radiographic CAP, and 55% received ED antibiotics. The median LOS was 41 h (IQR: 25, 54). After propensity analyses, there were no differences in LOS, escalated care, treatment failure, or revisits between children who received antibiotics and those who did not. Seventy-one percent of patients completed follow-up surveys after discharge. Among 16% of patients with fevers after discharge, the median fever duration was 2 days, and those who received antibiotics had a 37% decrease in the mean number of days with fever (95% confidence interval: 20% and 51%). We found no statistical differences in other QoL measures.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aftercare
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Community-Acquired Infections* / drug therapy
  • Fever / drug therapy
  • Humans
  • Patient Discharge
  • Pneumonia* / drug therapy
  • Prospective Studies
  • Quality of Life

Substances

  • Anti-Bacterial Agents